July 14, 2025

Predicting Naming Loss After Epilepsy Surgery

A study of patients who underwent epilepsy surgery in the language-dominant temporal lobe identified key risk factors for early naming decline and found that the degree of early decline predicts long-term recovery.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 24, 2025

AI vs. MDs: Who Navigates the Airways Better?

A new systematic review evaluated 20 studies on artificial intelligence in bronchoscopy and found AI systems often performed as well as or better than human experts in tasks such as airway navigation and lymph node classification.

Conexiant

May 22, 2025

At-Home HPV Test Matches Clinic Accuracy

Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.

Conexiant

April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

June 02, 2025

Restrictive Platelet Thresholds Endorsed in New Guidelines

International experts reviewed decades of data and endorsed lower platelet transfusion thresholds.

Conexiant

June 10, 2025

Cancer Pain Study Shows Promise for Novel Neurotoxin

A Phase I study of intrathecal resiniferatoxin in patients with advanced cancer pain shows promising reductions in pain and opioid use, with durable effects and manageable side effects.

Conexiant